

# The efficacy of a topical gel containing hyaluronic acid in the treatment of oral ulcers

<b>Submission date</b> 30/06/2020	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 15/07/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 15/07/2020	<b>Condition category</b> Oral Health	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Recurrent aphthous stomatitis (RAS) are common mouth ulcers. The cause of these ulcers are not always well understood, so treatment is mostly to treat the symptoms of the ulcer, to relieve pain and inflammation, and to accelerate the healing process. Medications applied directly to the ulcer have already been proved to be effective, however, more studies are needed to investigate the effectiveness of hyaluronic acid in the treatment of RAS to relieve pain and promote healing.

Most patients have their first experience of RAS between the ages of 10 and 19 years old and this may become less frequent with increasing age. Ulcers can heal spontaneously after one or two weeks but can then reoccur, this could be monthly or a few times per year.

The aim of this study is to assess the efficacy of hyaluronic-acid-based oral gel (Bexident® gel) in pain relief and ulcer healing.

### Who can participate?

Candidates aged 12 to 50 years old can participate. Participants must have a current complaint of an oral ulcer (sore) that is causing pain. It's also important to not have used any other medication to treat the oral sores in the previous 48 hours, nor to suffer from other diseases that could give rise to oral sores.

### What does the study involve?

Participants will be randomly allocated to relieve either the hyaluronic-acid-based oral gel (Bexident® gel), or a similar gel without hyaluronic acid. Participants will be asked to apply a gel on the sore for seven days and record the level of pain after each application according to certain instructions that will be given by the operators.

### What are the possible benefits and risks of participating?

A possible benefit of using the oral gel is faster healing and pain relief. Currently, there are no known risks for the use of the oral gel.

Where is the study run from?

The Department of Biomedical, Surgical and Dental Sciences, University of Milan (Italy).

When is the study starting and how long is it expected to run for?

From November 2018 to January 2019

Who is funding the study?

The University of Milan (Italy) and BMG Pharma (Italy)

Who is the main contact?

Prof. Chiara Occhipinti

Chiara.Occhipinti@unimi.it

## Contact information

### Type(s)

Scientific

### Contact name

Prof Chiara Occhipinti

### Contact details

Via della Commenda 10

Milan

Italy

20122

+393339155689

Chiara.Occhipinti@unimi.it

### Type(s)

Public

### Contact name

Dr Maggie Stephen F. Fahim

### Contact details

Via della Commenda 10

Milan

Italy

20122

+39 3491194721

maggiesteven00@hotmail.com

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

**ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

SKT\_MagF\_GMT.250620

## Study information

**Scientific Title**

The efficacy of a topical gel containing hyaluronic acid in the treatment of minor recurrent aphthous ulcers in an Italian cohort: a randomized, double-blind, placebo-controlled clinical trial

**Study objectives**

The aim of this randomized double-blind placebo-controlled clinical trial (RCT) is to evaluate the efficacy of a Hyaluronic Acid gel for the treatment of Recurrent Aphthous Stomata in an Italian cohort.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 19/09/2018, the Ethical Committee of the University of Milan (Via Festa del Perdono 7, 20122, Milan, Italy; +39 (0)2503111; comitato.etico@unimi.it), ref: 44/18

**Study design**

Randomized double-blind placebo-controlled parallel clinical trial

**Primary study design**

Interventional

**Secondary study design**

Randomised parallel trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

No participant information sheet available

**Health condition(s) or problem(s) studied**

Recurrent aphthous stomatitis

**Interventions**

70 patients with the complaint of RAS will be enrolled in this study, and will be randomly be assigned to the Test or the Placebo group in an equal ratio (1:1, 35 subjects in each group). The Test group is treated with Bexident® gel (Bexident Aftas Gel®, Barcelona, ISDIN). The medicated product contains polyvinylpyrrolidone (PVP), sodium hyaluronate and a few natural

extracts. For preparation of the placebo gel, all previous ingredients are used except for PVP and sodium hyaluronate. Both formulations are packed in the same kind of tubes containing 8 ml of product.

An investigator not involved in clinical examination randomly divides and assigns a numerical code to each tube. Then the codes are assigned to patients by means of a computer-generated number list and the tubes are then given to the clinical investigators who are blind to the treatment agents contained inside.

All patients and clinical investigators are blinded to the group assignment and to the products contained in the assigned product. All the participants are clinically examined to measure the size of each ulcer at baseline, the examinations are done by the same unique investigator on all occasions (CO).

A periodontal probe are used to measure the distance between two opposite outer edges of the white margin of the ulcer. Two measurements perpendicular to each other passing through the center of the lesion are obtained and then multiplied to calculate the cross-sectional area of the ulcer. If the patient showed more than one ulcer, only the greatest one is recorded.

A visual analog scale (VAS) consisting of a 10 cm horizontal line ranking from 0 (no pain) to 10 (unbearable pain) is used for patients to self-assess their pain.

Patients are instructed, to squeeze approximately 1 milliliter of the product on a finger or a cotton tip three times a day for one week and to gently rub it on each lesion. It is recommended to refrain from eating or drinking for 60 minutes after application. For each lesion, a total amount of at least 21 ml of product is used. On the VAS scale, the patients are instructed to mark the pain level every day before, right after, 20 and 60 minutes after drug application, from the first till the seventh day, for a total of 84 measurements for each patient.

The efficacy indices (EI) for ulcer pain are calculated at each time-point using the following formula:  $EI = [(V_x - V_1) \div V_1] \times 100\%$ ; with  $V_x$  referring to values measured within a particular time frame (in this study, at 2-7 days) and  $V_0$  referring to the baseline value to be measured at the first measurement (before the first application) on day 0. Efficacy indices (EI) are evaluated on a 4-rank scale: 1: healed,  $EI \geq 95\%$ ; 2: marked improvement,  $EI \geq 70\%$  to  $< 95\%$ ; 3: moderate improvement,  $EI \geq 30\%$  to  $< 70\%$ ; 4: no improvement,  $EI < 30\%$ . Patients are considered to have shown marked improvement rate (MIR) when EI was  $\geq 70\%$  and improvement rate (IR) when EI was  $\geq 30\%$  (34).

Patients are also asked to report every day any adverse effects and to not use any other products for the treatment of aphthous ulcers while participating in the study or to report it (and in that case, they would be excluded from the study). The used questionnaire was dichotomic yes/no. In case of positive answer, it is asked to describe what they have experienced.

The data are then analyzed by a third operator, who is blinded to the study and does not perform any treatment on the patients. Compliance is not assessed because the total product provided to each patient was just sufficient for the designated dose and time frame of treatment.

## **Intervention Type**

Drug

## **Phase**

## Phase III

### Drug/device/biological/vaccine name(s)

Bexident® gel (Bexident Aftas Gel®, Barcelona, ISDIN)

### Primary outcome measure

Pain is measured using a visual analogue scale (VAS) at baseline, then before, right after, 20 and 60 min after drug application, three times daily, for seven days (a total of 84 measurements for each patient)

### Secondary outcome measures

Change in ulcer size is measured using a periodontal probe, two measurements of the distance between the two opposite outer edges of the white margin of the ulcer perpendicular to each other passing through the center of the lesion will be obtained and then multiplied to calculate the cross-sectional area of the ulcer, at baseline, then every 24 h for 7 days

### Overall study start date

01/10/2018

### Completion date

30/01/2019

## Eligibility

### Key inclusion criteria

1. Aged between 12 and 50 years
2. Presence of at least one aphthous ulcer in an easily accessible area of the mouth and reporting pain

### Participant type(s)

Patient

### Age group

Mixed

### Sex

Both

### Target number of participants

70

### Total final enrolment

70

### Key exclusion criteria

1. Pregnancy and lactation
2. Systemic disease such as Crohn's disease, Behçet's syndrome or ulcerative colitis
3. HIV, hepatitis C, or other systemic, acute or chronic infections
4. Use of other medications or drugs within 2 months, and specifically use of any local treatment for ulcers within 48 h of the start of the study

**Date of first enrolment**

22/10/2018

**Date of final enrolment**

21/12/2018

## **Locations**

**Countries of recruitment**

Italy

**Study participating centre****University of Milan**

Via della Commenda 10

Department of Surgical, Biomedical and Dental Sciences

Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico

Milan

Italy

20122

## **Sponsor information**

**Organisation**

University of Milan

**Sponsor details**

Via della Commenda 10

Milan

Italy

20122

+393339155689

giampietro.farronato@unimi.it

**Sponsor type**

University/education

**Website**

<http://www.unimi.it/ENG/>

**ROR**

<https://ror.org/00wjc7c48>

# Funder(s)

## Funder type

Industry

## Funder Name

BMG Pharma

## Funder Name

Università degli Studi di Milano

## Alternative Name(s)

Universitas Studiorum Mediolanensis, University of Milan, La Statale, UniMi

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Universities (academic only)

## Location

Italy

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

## Intention to publish date

01/11/2020

## Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be included in the subsequent results publication.

## IPD sharing plan summary

Other